Marketed & Developmental Products

The following table summarizes the status of products marketed, approved and/or under development by Noven.

Product

Indication

Regulatory Status

Marketing Rights

Noven Therapeutics

Pexeva®
 (paroxetine mesylate)

Depression, panic disorder, OCD & GAD Marketed in U.S. Noven
Lithobid®
 (lithium carbonate) 		Bipolar disorder Marketed in U.S. Noven
Stavzor®
 (valproic acid)
Delayed Release Capsules		 Bipolar disorder, migraine & epilepsy Marketed in U.S. Noven
MesafemTM
 (low-dose paroxetine mesylate) 		Vasomotor symptoms (hot flashes) Entering Phase 3 Noven

Transdermal Hormone Therapy

Advanced Generation Estrogen
Vivelle-Dot®/
Estradot®

 Menopausal symptoms/
osteoporosis
FDA-approved; Approved in over 45 foreign countries Novogyne1--U.S.  Aventis2--Japan
Novartis Pharma3--all other territories

Combination
Estrogen/Progestin CombiPatch®/Estalis®

 Menopausal symptoms FDA-approved; Approved in over 30 foreign countries

Novogyne--U.S.
Aventis--Japan
 Novartis Pharma--all other territories
Transdermal ADHD    
Methylphenidate
Daytrana®
 ADHD FDA-approved
 Shire4--worldwide
Amphetamine ADHD Pre-clinical Noven
1
 Novogyne Pharmaceuticals is a joint venture between Noven and Novartis Pharmaceuticals Corporation.
2
 Aventis S.A.
3
 Novartis Pharma AG.
4

Shire plc

Copyright © 2010 Noven Pharmaceuticals, Inc. All rights reserved.